MAI Capital Management’s Intellia Therapeutics NTLA Stock Holding History

MAI Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,340	Closed	-$17.2K	–	3808
2026 Q1	$17.2K	Buy	1,340 +1,145	+587%	+$14.6K	﹤0.01%	2880
2025 Q4	$1.75K	Hold	195	–	–	﹤0.01%	3448
2025 Q3	$3.37K	Hold	195	–	–	﹤0.01%	3162
2025 Q2	$1.83K	Buy	195 +67	+52%	+$550	﹤0.01%	3447
2025 Q1	$911	Hold	128	–	–	﹤0.01%	3155
2024 Q4	$1.49K	Buy	+128	New	+$2K	﹤0.01%	3096

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

MAI Capital Management's NTLA Position: Q2 2026 in Review

MAI Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 1,340 shares — an estimated $17.2K sold.

MAI Capital Management first reported a position in NTLA in Q4 2024 and held it in 6 quarters. The position peaked at $17.2K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

MAI Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 1,340 Intellia Therapeutics shares in Q2 2026, an estimated $17.2K.
MAI Capital Management first reported a position in Intellia Therapeutics in Q4 2024 and held it in 6 quarters.
MAI Capital Management's Intellia Therapeutics position peaked at $17.2K in Q1 2026.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.